CLEVELAND, March 14, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today the initiation of patient enrollment, and dosing of the first patient for a Phase II clinical trial evaluating the safety and efficacy of administration of MultiStem ®, Athersys' allogeneic cell therapy product for the treatment of ulcerative colitis (UC). This Phase II clinical trial is part of a strategic global collaboration between Athersys and Pfizer Inc. (NYSE:PFE) to investigate MultiStem for the treatment of inflammatory bowel disease (IBD).
Athersys Announces Initiation Of Patient Enrollment For Phase II Clinical Trial In Inflammatory Bowel Disease
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.